key: cord-0974678-nuqj4u59
authors: Xue, Ling; Jing, Shuanglin; Zhang, Kai; Milne, Russell; Wang, Hao
title: Infectivity versus fatality of SARS-CoV-2 mutations and influenza
date: 2022-05-15
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2022.05.031
sha: b8d0c4d9ed5316dcde145009de95f5fa220bfeb0
doc_id: 974678
cord_uid: nuqj4u59

Objectives : Due to the spread of the Omicron variant, many countries have experienced COVID-19 case numbers unseen since the start of the pandemic. We aimed to compare the epidemiological characteristics of Omicron with prior variants and different strains of influenza, to provide context for public health responses. Methods : We developed transmission models for SARS-CoV-2 variants as well as influenza, in which transmission, death, and vaccination rates were taken to be time-varying. We fit our model based on publicly available data in South Africa, the United States and Canada. We used this model to evaluate the relative transmissibility and mortality of Omicron compared to previous variants and influenza. Results : We find that Omicron is more transmissible and less fatal than both seasonal and 2009 H1N1 influenza, as well as the Delta variant; these characteristics make Omicron epidemiologically more similar to influenza than it is to Delta. We estimate that as of February 7, 2022, booster doses have prevented 4.29 × 10 7 and 1.14 × 10 6 Omicron infections in the United States and Canada, respectively. Conclusions : Our findings indicate that the high infectivity of Omicron will keep COVID-19 endemic, similarly to influenza. However, due to Omicron's lower fatality rate, our work suggests that human populations living with SARS-CoV-2 is most likely.

On January 30, 2020, the World Health Organization declared coronavirus disease 2019 , which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to be a public health emergency (WHO 2021c). The ongoing COVID-19 pandemic presents great threats to public health and significant challenges to global economic development. To illustrate this, as of February 20, 2022, the COVID-19 epidemic has caused over 422 million confirmed cases worldwide, as well as a number of confirmed deaths approaching 5.8 million (WHO 2021a) . The rapid mutation rate of the COVID-19 virus is also an important reason for its great and long-lasting impact (Yu et al. 2021) : the successive emergence of SARS-CoV-2 variants has caused a worldwide multi-wave epidemic of COVID-19. In November 2021, the Omicron variant (B.1.1.529) was first discovered in Gauteng, South Africa; its swift spread led to the fourth wave of the COVID-19 pandemic (Maslo et al. 2022 , Planas et al. 2022 ).

In the first two months following its discovery, the Omicron variant was identified in 110 countries across all six WHO Regions (WHO 2021b), and its infection rate has been identified as being significantly faster than that of the Delta variant (Wei et al. 2021 , WHO 2021b . As a result of its fast spread, Omicron has come under intense study (Cameroni et al. 2022 , Cao et al. 2022 , Cele et al. 2022 , Liu et al. 2022 , Planas et al. 2022 . Using high-throughput yeast display screening, Cao et al. found that mutations present in Omicron allowed it to escape from more than 85% of tested neutralizing antibodies targeting its receptor-binding domain (Cao et al. 2022 ).

Furthermore, Liu et al. found that Omicron is markedly resistant to neutralization by serum not only from convalescent patients, but also from individuals vaccinated with one of four widely used COVID-19 vaccines (Pfizer, Moderna, J & J, and AstraZeneca) (Liu et al. 2022) . Planas et al. found that Omicron often escapes from both monoclonal and vaccine-elicited antibodies (Planas et al. 2022 ). However, their results also included that antibodies generated by a recent booster vaccine dose could neutralize Omicron (Planas et al. 2022) , albeit less effectively compared to other SARS-CoV-2 variants.

Mathematical models can be used to understand the dynamics of SARS-CoV-2 variants and help inform effective control strategies, and many modelling studies have hence been performed to make projections about the spread of these variants Rocklöv 2021, Yu et al. 2021) . In a literature review, Liu and Rocklöv found that estimates of Delta's basic reproductive number ranged from 3.2 to 8, with a mean of 5.08, much higher than that of the ancestral strain (Liu and Rocklöv 2021) . Yu et al. used mathematical models to estimate the relative transmissibility of Omicron using variant proportion data in South Africa, finding that it is more transmissible than Delta by a factor of approximately 3.8 (Yu et al. 2021) . Similarly, Chen et al. found that Omicron is more transmissible than Delta by a factor of 2.8 using an AI model (Chen et al. 2022 ).

However, as the Omicron variant is still new, our understanding of its infectivity and fatality, as well as how these compare to other variants, is still evolving. Additionally, to the best of our knowledge, the question of how the epidemiological properties of Omicron compare to those of other fast-spreading viruses such as influenza has not yet been addressed. To evaluate the properties of the Omicron variant, we develop a mathematical model in which transmission, death, and vaccination rates are all time-varying. We fit our model using the numbers of new confirmed cases of the Delta and Omicron variants, as well as all other variants in aggregate (e.g. Beta, Gamma, Epsilon), in South Africa, the United States, and Canada, as well as the numbers of individuals who have been fully vaccinated and who have received booster doses in those countries. Following this, we computed the transmission rate, death rate, and effective reproduction number of Delta, Omicron, and the other variants in each study jurisdiction. We also computed these statistics for seasonal influenza and the 2009 strain of H1N1 influenza in the United States and Canada by fitting case and death data to another model (see SI Appendix). The epidemic curves produced by our model fit the data very well, indicating that our model captures the dynamics of the COVID-19 virus variants.

To understand the impact of the SARS-CoV-2 variants on the spread of the COVID-19 epidemic, we collected data on the proportions of all SARS-CoV-2 infections that each of the variants accounted for (OWID 2021) . This data was reported every two weeks from May 18, 2020 to February 7, 2022 in South Africa, the United States, and Canada (Fig. A1) . We also collected daily numbers of new confirmed cases and new deaths (CDC 2021 , OWID 2021 , as well as the number of fully vaccinated individuals, broken down into those with and without booster doses (Mathieu et al. 2021) . We used the relative prevalences of the SARS-CoV-2 variants to calculate the daily numbers of new confirmed cases infected by Delta, Omicron, and all other variants in our study countries. Similarly, we calculated the daily number of new deaths in the study countries from Delta, Omicron, and all other variants by scaling total COVID-19 deaths by the proportions of each SARS-CoV-2 variant from two weeks prior.

To mimic the spread of COVID-19, we constructed a disease transmission model with vaccination. The total population (denoted by ) is divided into eight classes, namely , 

The model time step is one day. , , , and are all time-varying parameters, which were dynamically fitted using a MCMC method (Haario et al. 2001 (Haario et al. , 2006 . All parameters are listed in Table 1 ; model parametrization is detailed in the SI Appendix.

According to the next generation matrix approach (van den Driessche and Watmough 2002), the effective reproduction number, , can be expressed as

incorporating the daily numbers of new cases generated by exposed, symptomatic, and asymptomatic individuals. The basic reproduction number is commonly used to measure transmission potential at the beginning of an epidemic (Diekmann et al. 1990 ). However, transmission potential varies over the course of an outbreak, and it can be measured at any time by the effective reproduction number.

For each SARS-CoV-2 variant, we estimated its transmission rates in South Africa, the United States, and Canada based on data from the time periods in each country during which it first emerged. We performed our analysis with both raw case numbers (Figs. 1, B2, and B3) and 7day averaged data (Figs. E10, E11, and E12). The two cubic splines that we used for transmission rate (based on the raw and smoothed data) were highly similar for all variants and countries (Figs. 2, E13 and E14), showing the robustness of our methods.

In South Africa, the average transmission rate of the Omicron variant was 0.4201 from November 1, 2021 to December 26, 2021 ( Fig. 1(A) ). For Delta, this was 0.1264 from March 9, 2021 to May 2, 2021 ( Fig. 1(C) ), and for all other variants it was 0.1629 from March 5, 2020 to April 28, 2020 ( Fig. 1(E) ). We estimate that Omicron's transmission rate is 3.3 times that of Delta and 2.6 times that of the other variants in South Africa; these values are consistent with previous studies (Yu et al. 2021 , Chen et al. 2022 ).

In the United States, Omicron's average transmission rate was 0.6794 from November 21, 2021

to December 26, 2021 ( Fig. B2(A) ). This was 0.1981 for Delta from May 2, 2021 to June 6, 2021 times that of Delta and other variants, respectively.

We estimated the lethality of the different variants by using their average death rates. For Delta, Omicron, and other variants in aggregate, these are 0.0020, , and 0.0022 in South (D), (F)). Delta's death rate in Canada is higher than that of Omicron by a factor of 3.1; for the other variants, this factor is 7.4. The above analysis shows that Delta and especially Omicron have lower death rates than previous variants.

To calculate the effective reproduction numbers for each SARS-CoV-2 variant, we substituted the estimated parameters into Eq. (2) Delta's in Canada. Likewise, the average effective reproduction number for Omicron was 5.2, 1.7, and 3.5 times that of variants other than Omicron and Delta in those three countries.

We additionally determined the protection rate of booster doses against infection by Omicron in the United States and Canada, as shown in Fig. 4 .

Africa began on January 17, 2022, we did not consider the effectiveness of booster doses on Omicron there.) As of February 7, 2022, we find that vaccination has reduced the number of infected people by and in the United States and Canada, respectively, and reduced the number of deaths by and in those countries. These results imply that with 70% protection against Omicron (see Table 1 ), booster doses of currently available vaccines can significantly reduce mortality.

To estimate the transmission and death rates of seasonal influenza, we collected weekly numbers of new confirmed cases and deaths from August 6, 2017 to December 22, 2019 in the United States and Canada. We used these to fit a seasonal influenza transmission model (see SI Appendix); our parameter fitting, using the same methods as for Model (1) (Yin et al. 2020) . In contrast to early variants of SARS-CoV-2, which were observed to have higher mortality rates than 2009 H1N1 influenza (da Costa et al. 2020), we found Omicron to be less deadly than that strain. We also found Omicron to be more transmissible than the tested varieties of influenza. Our results indicate that although Omicron must be taken seriously due to its high infectivity, its low fatality suggests that it can serve as a less dangerous replacement for other SARS-CoV-2 strains, outcompeting them but causing less damage.

We found that the Omicron variant is epidemiologically more similar to influenza than previous SARS-CoV-2 variants; this is evident by its unique mutations, which confer upon it a different evolutionary strategy (Du et al. 2022) . Hence, we predict that methods for combatting Omicron based on previous public health responses to seasonal influenza will be effective. Earlier in the COVID-19 pandemic, it was found that non-pharmaceutical interventions to suppress COVID-19

in China also had the effect of suppressing seasonal influenza cases, since the two diseases share similar transmission methods (Lei et al. 2020) . Seasonal influenza is characterized by wintertime outbreak peaks and yearly variability in epidemiological characteristics (Chowell et al. 2008) . So far, the COVID-19 pandemic has also exhibited these features, with new SARS-CoV-2 variants emerging at least once per year. Further variants in Omicron's lineage have been observed (Desingu et al. 2022) , and due to Omicron's ubiquity, the next dominant variant may be one of its descendants. Therefore, as the future of the COVID-19 pandemic may revolve around managing viruses with similar characteristics as Omicron, applying strategies originally designed for seasonal influenza will prove useful.

Our study still has several limitations. First, since the numbers of recovered and asymptomatic infected individuals are not publicly available yet, our simulations only used incidence data, death cases and the number of fully vaccinated individuals. Second, the numbers of new confirmed cases and deaths for each variant are intertwined with the reported data, and hard to disentangle from it. We used the proportions of cases caused by each SARS-CoV-2 variant to calculate these numbers. Third, we used Model (1) to fit three SARS-CoV-2 variants under the assumption that an individual can be simultaneously infected with different variants. Fourth, we did not consider human mobility and imported cases from overseas, or the role of environmental factors; these will be studied when such data become available.

The authors declare that they have no conflicts of interest.

Research Funds for the Central Universities of China 3072020CFT2402. HW is partially supported by NSERC Individual Discovery Grant RGPIN-2020-03911 and NSERC Discovery Accelerator Supplement Award RGPAS-2020-00090.

This article does not contain any studies involving animals or humans performed by any of the authors.

H.W. designed research; all authors conceived the work; S.J., K.Z., and H.W. performed research; all authors analyzed data; L.X., S.J., and K.Z. wrote the initial draft; all authors edited the manuscript. Probability that an individual will be completely protected from COVID-19 after for variants other than Delta and Omicron, 7 for Delta, and 6 for Omicron. In each subplot, the red curve represents the mean simulated number of cases or deaths, and the blue curve represents the transmission or death rate. The 95% prediction and confidence intervals are plotted in pink and magenta, respectively. show the fitting of those variants' death rates. The transmission rates were taken to be cubic splines, with numbers of nodes equal to 14 for variants other than Delta and Omicron, 6 for Delta, and 6 for Omicron. In each subplot, the red curve represents the mean simulated number of cases or deaths, and the blue curve represents the transmission or death rate. The 95%

prediction and confidence intervals are plotted in pink and magenta, respectively. for Omicron; these node numbers were the same as the ones used when fitting to non-averaged data in South Africa. In each subplot, the red curve represents the mean simulated number of cases or deaths, and the blue curve represents the transmission or death rate. The 95% prediction and confidence intervals are plotted in pink and magenta, respectively. for Omicron; these node numbers were the same as the ones used when fitting to non-averaged data in the United States. In each subplot, the red curve represents the mean simulated number of cases or deaths, and the blue curve represents the transmission or death rate. The 95% prediction and confidence intervals are plotted in pink and magenta, respectively. these node numbers were the same as the ones used when fitting to non-averaged data in Canada.

In each subplot, the red curve represents the mean simulated number of cases or deaths, and the blue curve represents the transmission or death rate. The 95% prediction and confidence intervals are plotted in pink and magenta, respectively. 

Comparison of clinical characteristics and disease outcome of COVID-19 and seasonal influenza

Broadly neutralizing antibodies overcome SARS-CoV

Omicron antigenic shift

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

Omicron variant (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance

Seasonal influenza in the United States, France, and Australia: transmission and prospects for control

Trends in Number of COVID-19 Cases and Deaths in the US Reported to CDC

Comparative epidemiology between the 2009 H1N1 influenza and COVID-19 pandemics

Confronting the Delta variant of SARS-CoV-2

Emergence of Omicron third lineage BA.3 and its importance

On the definition and the computation of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations

Omicron adopts a different strategy from Delta and other variants to adapt to host

Assessment of deaths from COVID-19 and from seasonal influenza

An adaptive Metropolis algorithm

DRAM: efficient adaptive MCMC

Echoes of 2009 H1N1 influenza pandemic in the Covid pandemic

Nonpharmaceutical interventions used to control COVID-19 reduced seasonal influenza transmission in China

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus

Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron wave compared with previous waves

A global database of COVID-19 vaccinations

The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all?

Our World in Data, SARS-CoV-2 variants in analyzed sequences in South Africa

van den Driessche P, Watmough J. Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission

Evidence for a mouse origin of the SARS-CoV-2 Omicron variant

World Health Organization, Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update

Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for Member States

WHO Director-General's statement on IHR Emergency Committee on Novel Coronavirus

Comparative evaluation of clinical manifestations and risk of death in patients admitted to hospital with COVID-19 and seasonal influenza: cohort study

A comparison of clinical and chest CT findings in patients with influenza A (H1N1) virus infection

A simple model to estimate the transmissibility of SARS

Delta and Omicron variants in South Africa